Send to

Choose Destination
Clin Ophthalmol. 2016 Mar 8;10:411-8. doi: 10.2147/OPTH.S98853. eCollection 2016.

Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials.

Author information

Duke Eye Center, Duke University Medical Center, Durham, NC, USA; Surgical Service, Durham Veterans Affairs Medical Center, Durham, NC, USA.


For years, the standard of care for branch-retinal-vein-occlusion-associated macular edema was initial observation followed by grid-pattern laser photocoagulation for persistent edema. Newer pharmacologic options have revolutionized the management of branch-retinal-vein-occlusion-associated macular edema, and the visual outcomes of these eyes are better than ever. However, a variety of available treatment options including intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factor agents have established novel challenges with regard to appropriate drug selection. This review summarizes the available clinical studies with special emphasis on the comparison of intravitreal aflibercept with ranibizumab, bevacizumab, and steroid agents.


BRVO; anti-vascular endothelial growth factor; bevacizumab; branch retinal vein occlusion; cystoid macular edema; dexamethasone implant; grid-pattern laser photocoagulation; macular edema; pegaptanib; ranibizumab; triamcinolone

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center